Blue Lake Biotechnology Inc, a clinical-stage intranasal vaccine company, on Monday reported the presentation of interim data from the company's Phase 1/2a paediatric clinical trial of RSV vaccine candidate BLB201 as a late-breaking abstract at the International Society for Vaccines 2026 Annual Congress in Antwerp, Belgium.
BLB201 is an intranasal RSV vaccine candidate being evaluated in Phase 1/2a clinical testing in children aged 8 to 59 months. It uses a proprietary PIV5 vector to express the RSV-F protein.
Interim data indicated that BLB201 may prevent symptomatic RSV infection in young children.
BLB201 has received Fast Track designation from the US Food and Drug Administration for prevention of RSV-associated acute respiratory disease in adults aged over 60 years and paediatric populations.
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
Akeso reports first patient dosed in Phase III study of cadonilimab in colon cancer
Sophos IRB and ALCMI partner to support lung cancer research
MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK
AstraZeneca invests USD2bn in Summit Therapeutics to advance ADC and cancer-drug combinations
QIAGEN completes US QIAstat-Dx bloodstream infection portfolio with FDA clearance
Innovent expands global Phase 3 study of IBI363/TAK-928 to include non-squamous NSCLC
Astellas doses first patient in Phase 3 lung cancer study
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
Insmed's ARIKAYCE sNDA granted priority review by FDA
Precigen announces FDA platform technology designation for AdenoVerse
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer